Kisspeptin: A Key Regulator of Reproductive Health and Hormonal Balance

Kisspeptin is a peptide hormone that plays a central role in controlling the reproductive endocrine system. Discovered in the late 20th century (initially noted for its anti-metastatic properties), it was soon recognized as an essential gatekeeper of puberty and fertility ( Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction - PMC ) ( Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction - PMC ). Kisspeptin is encoded by the KISS1 gene and acts via the GPR54/KISS1R receptor on gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus. By activating these GnRH neurons, kisspeptin triggers the release of GnRH in a pulsatile manner, which in turn stimulates the pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (Exogenous kisspeptin administration as a probe of GnRH neuronal function in patients with idiopathic hypogonadotropic hypogonadism - PubMed) (Kisspeptin and neurokinin B: roles in reproductive health - PubMed). Through this mechanism, kisspeptin sits at the apex of the hypothalamic-pituitary-gonadal (HPG) axis, orchestrating hormonal cascades that regulate sexual development and reproductive function.

Mechanism of Action in the HPG Axis

Kisspeptin binds to its receptor (KISS1R) on GnRH neurons, leading to activation of intracellular signaling (Gq/11 -> PLC pathway) that culminates in GnRH secretion ( Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction - PMC ). This GnRH release is critical for the pulsatile stimulation of the anterior pituitary. In response to GnRH pulses, the pituitary releases LH and FSH, which act on the gonads. In both sexes, this stimulates sex steroid production (estrogen, progesterone, testosterone) and gametogenesis (spermatogenesis in males, follicular development and ovulation in females) (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female) (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female). Kisspeptin neurons themselves are sensitive to steroid feedback: they possess estrogen and progesterone receptors, enabling sex hormones to modulate kisspeptin’s activity. This feedback integration allows kisspeptin to maintain hormonal balance – for example, high sex steroid levels signal kisspeptin neurons to reduce GnRH drive (negative feedback), whereas in females a surge in estrogen can paradoxically stimulate a subset of kisspeptin neurons to induce the ovulatory surge (positive feedback) as described below (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female).

Notably, kisspeptin neurons co-express neurokinin B (NKB) and dynorphin (often termed KNDy neurons) in the hypothalamic arcuate nucleus. This KNDy network is believed to generate the rhythmic oscillations of GnRH/LH pulses. Kisspeptin provides the excitatory drive to GnRH neurons, NKB helps synchronize neuronal activity, and dynorphin provides inhibitory timing, together producing a pulse generator for GnRH release. This mechanism underlies the regular pulsatile secretion of gonadotropins required for normal reproductive function (Kisspeptin and neurokinin B: roles in reproductive health - PubMed). In summary, kisspeptin’s mechanism of action is to serve as the master upstream signal that unleashes GnRH, thereby governing downstream reproductive hormones. Indeed, exogenous kisspeptin is a potent stimulus for GnRH and can acutely increase LH/FSH secretion in humans (Exogenous kisspeptin administration as a probe of GnRH neuronal function in patients with idiopathic hypogonadotropic hypogonadism - PubMed). The crucial importance of this mechanism is evident from human mutations: loss-of-function in KISS1 or KISS1R causes hypogonadotropic hypogonadism (failure of puberty and infertility), underscoring that kisspeptin signaling is indispensable for HPG axis activation ( Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction - PMC ).

Role of Kisspeptin in Female Reproductive Health

In females, kisspeptin is integral to virtually every stage of reproductive health:

• Puberty and Adolescence: The rise in kisspeptin signaling is thought to trigger the onset of puberty in girls. Prior to puberty, GnRH release is low; the activation of kisspeptin neurons in late childhood initiates GnRH pulsatility and hence the secretion of LH/FSH that drive ovarian estrogen production. This leads to breast development, menarche (the first menstrual period), and the ability to ovulate. Kisspeptin has been shown to be essential for puberty initiation – studies of girls with impaired kisspeptin signaling (genetic mutations) demonstrate absent or delayed puberty ( Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction - PMC ).

• Menstrual Cycle Regulation: Kisspeptin coordinates the menstrual cycle by modulating GnRH/LH/FSH levels throughout the cycle. During the follicular phase, kisspeptin neurons in the arcuate nucleus (ARC) mediate negative feedback: as estrogen rises moderately, kisspeptin keeps GnRH pulses in check to prevent premature LH surges. However, at mid-cycle when estrogen levels peak, a distinct population of kisspeptin neurons in the anteroventral periventricular nucleus (AVPV) is stimulated by this high estrogen – resulting in a dramatic surge of kisspeptin release (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female). This kisspeptin surge triggers a massive GnRH discharge, causing the pituitary LH surge that induces ovulation (release of the egg) (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female). In essence, kisspeptin is the critical mediator of the positive feedback effect of estradiol that produces the ovulatory LH surge. Without kisspeptin, this surge (and thus ovulation) does not occur. After ovulation, during the luteal phase, rising progesterone (and estrogen) again provide negative feedback through kisspeptin neurons (largely in the ARC) to suppress GnRH and prevent another surge in the same cycle. This delicate dance ensures regular cyclicity and is orchestrated by kisspeptin at the hypothalamic level.

• Pregnancy and Placental Function: Kisspeptin also plays a role during pregnancy. The placenta expresses very high levels of kisspeptin (much higher than the brain), which enters the maternal circulation. While placental kisspeptin does not feedback to GnRH neurons, it is thought to regulate trophoblast invasion and placental development – essentially acting as a local hormone to maintain placental function and perhaps prevent excessive invasion of the uterus by placental cells (Kisspeptin and neurokinin B: roles in reproductive health - PubMed). Proper placental kisspeptin levels have been associated with healthy pregnancy outcomes, and aberrant levels are being investigated in complications like pre-eclampsia and gestational trophoblastic diseases. Furthermore, kisspeptin levels rise progressively during normal pregnancy (due to placental production), and drop sharply after delivery, though the physiological significance of this maternal circulation spike is still under study.

• Menopause: As women enter menopause and ovarian estrogen production falls, the loss of estrogen negative feedback leads to increased kisspeptin/NKB activity in the hypothalamus (Kisspeptin and neurokinin B: roles in reproductive health - PubMed). This upregulation is implicated in generating menopausal symptoms such as hot flashes. (In fact, drugs targeting the NKB/kisspeptin pathway – e.g. NKB receptor antagonists like fezolinetant – have been developed to alleviate hot flashes (Kisspeptin and neurokinin B: roles in reproductive health - PubMed). Kisspeptin itself is not directly given for menopause, but the research highlights its involvement in the neuroendocrine changes of menopause.)

Overall, in women, kisspeptin is vital for reproductive health: it enables pubertal maturation, maintains the menstrual cycle and fertility, supports healthy pregnancy, and is intertwined with the hormonal changes across the reproductive lifespan (Kisspeptin and neurokinin B: roles in reproductive health - PubMed). Without adequate kisspeptin signaling, women may experience amenorrhea (absent periods), infertility, or failure to undergo puberty.

Role of Kisspeptin in Male Reproductive Health

In men, kisspeptin is equally fundamental, though the dynamics differ from women. During puberty in males, increased kisspeptin release in the hypothalamus kick-starts GnRH pulsatility, leading to the rise in LH and FSH that drives testicular maturation. LH stimulates Leydig cells in the testes to produce testosterone, and FSH acts on Sertoli cells to support spermatogenesis (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female). If kisspeptin or its receptor is non-functional, the male will have hypogonadotropic hypogonadism – presenting with lack of sexual development, low testosterone, and infertility (analogous to Kallmann syndrome or other forms of GnRH deficiency).

In the adult male, kisspeptin provides the tonic drive for the HPG axis. GnRH neurons receive continuous (pulsatile) stimulation from kisspeptin neurons (primarily in the arcuate nucleus), resulting in regular LH/FSH pulses that maintain testosterone production and sperm generation (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female). Unlike the cyclic pattern in females, male kisspeptin-GnRH release is relatively constant in frequency (there is no monthly cycle). Testosterone and its metabolites (estradiol, dihydrotestosterone) feed back on kisspeptin neurons to modulate this activity – high levels suppress kisspeptin and GnRH release (negative feedback) to keep testosterone in a normal range (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female). Notably, males lack an estrogen-driven positive feedback surge. This is because testosterone is not produced in a cyclical surge manner and the male hypothalamus does not mount an LH surge. Correspondingly, males do not have the dense population of AVPV kisspeptin neurons that females do (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female). Instead, male reproductive function relies on the baseline (tonic) kisspeptin input to GnRH neurons.

Despite having fewer kisspeptin neurons, men still require kisspeptin’s activity for fertility. Experiments show that administering exogenous kisspeptin to men acutely raises LH and testosterone levels, confirming that the pathway is active and responsive (Exogenous kisspeptin administration as a probe of GnRH neuronal function in patients with idiopathic hypogonadotropic hypogonadism - PubMed). Some research also indicates kisspeptin might influence male sexual behavior: for example, kisspeptin administration in men can heighten brain activity related to sexual arousal without necessarily changing testosterone acutely (Kisspeptin hormone injection could treat low sex drive in women and men | Imperial News | Imperial College London) (Kisspeptin hormone injection could treat low sex drive in women and men | Imperial News | Imperial College London). In summary, in males, kisspeptin ensures the maintenance of hormonal output (testosterone) and sperm production, enabling normal libido, spermatogenesis, and male fertility. A deficiency in kisspeptin signaling in men leads to low testosterone, poor sperm counts, and infertility, highlighting its importance in male hormonal regulation.

Sex Differences in Kisspeptin Signaling

(Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female) Comparison of

female (left) and male (right) HPG axes. Kisspeptin neurons (pink) are present in both sexes, but females have an additional population in the AVPV/POA region that mediates the estrogen-driven GnRH/LH surge for ovulation (a mechanism absent in males). Both sexes have kisspeptin neurons in the arcuate nucleus (ARC) that drive pulsatile GnRH release (tonic regulation). FSH and LH from the pituitary act on the ovaries or testes to produce sex steroids and gametes, which feedback to the brain.

There are clear sexual dimorphisms in the kisspeptin system. The most notable difference is the presence of two functionally distinct kisspeptin neuron populations in females (ARC and AVPV), versus primarily one in males (ARC). Females possess a much higher number of kisspeptin neurons in the AVPV/rostral hypothalamus, which are activated by rising estradiol to induce the preovulatory GnRH/LH surge (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female) (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female). Males, by contrast, have very few kisspeptin neurons in this region and do not generate an LH surge (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female) (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female). Instead, male GnRH release is governed by the ARC kisspeptin neurons that provide steady pulsatile signals. This anatomical and functional difference underlies why positive feedback by estrogen (and the associated cyclic ovulatory mechanism) exists only in females.

Despite these differences, kisspeptin’s fundamental role as the trigger for GnRH is common to both sexes. In both men and women, arcuate kisspeptin (often co-expressing NKB and dynorphin) generates the baseline pulsatile GnRH drive required for gametogenesis and gonadal steroid production (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female). Both sexes also rely on kisspeptin for puberty onset and for maintaining appropriate hormone levels through negative feedback loops. The key distinctions can be summarized as follows: females have an extra surge mode of kisspeptin release (leading to cyclic ovulation) and higher kisspeptin neuron density, whereas males rely solely on tonic kisspeptin input without an analogous surge. These differences highlight how kisspeptin adapts the HPG axis to the distinct reproductive strategies of each sex.

Benefits and Clinical Applications of Kisspeptin

Beyond its fundamental physiological roles, kisspeptin has attracted interest for clinical applications in reproductive health. Researchers are leveraging our understanding of kisspeptin’s mechanisms to develop therapies or diagnostic tools. Some notable applications and potential benefits include:

• Fertility Treatments (Ovulation Induction in IVF): One of the most promising uses of kisspeptin is as a trigger for ovulation in assisted reproduction. Traditionally, IVF treatments use hCG injections to induce final oocyte maturation, but hCG can cause ovarian hyperstimulation syndrome (OHSS) in high-risk patients. Kisspeptin offers a safer, more physiological alternative. Since kisspeptin is the natural trigger of GnRH and LH surge, giving a dose of kisspeptin can induce ovulation in a controlled way (Kisspeptin and neurokinin B: roles in reproductive health - PubMed). Clinical trials in women at high risk of OHSS have shown that a single injection of kisspeptin-54 successfully matured eggs in ~95% of patients, with high rates of successful embryo development and live births (Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy - PubMed). Moreover, the incidence of OHSS was markedly lower compared to hCG-based protocols. Thus, kisspeptin is being explored as an ovulation trigger in IVF to improve safety and outcomes (Kisspeptin and neurokinin B: roles in reproductive health - PubMed). Ongoing research includes optimized dosing (even multiple kisspeptin doses) and development of longer-acting kisspeptin analogs (such as MVT-602) to further enhance its utility in fertility treatments.

• Hypogonadotropic Hypogonadism and Pubertal Disorders: Because kisspeptin directly stimulates GnRH, it can be used to test the functional capacity of the GnRH neurons in patients with delayed puberty or suspected GnRH deficiency. For example, administering kisspeptin to a patient can help distinguish constitutional delayed puberty from idiopathic hypogonadotropic hypogonadism (IHH); in IHH cases with GnRH neuron dysfunction, exogenous kisspeptin fails to elicit an LH response (Exogenous kisspeptin administration as a probe of GnRH neuronal function in patients with idiopathic hypogonadotropic hypogonadism - PubMed). In contrast, a robust response suggests GnRH neurons are intact. Therapeutically, kisspeptin or its analogs might in the future be used to treat certain forms of GnRH deficiency or to kick-start puberty, although GnRH therapy is more established and thus kisspeptin use here is still investigational. Nonetheless, early trials are examining kisspeptin in teens with pubertal delay and in adults with congenital hypogonadism as a novel way to stimulate the reproductive axis.

• Functional Hypothalamic Amenorrhea (FHA): FHA is a reversible form of amenorrhea (loss of menstrual cycles) often caused by stress, weight loss, or excessive exercise, leading to reduced GnRH drive. Kisspeptin neurons are known to be very sensitive to metabolic and stress signals; low energy availability or high stress can suppress kisspeptin release, resulting in low GnRH and hence amenorrhea. Given this understanding, researchers have tested kisspeptin as a therapy to restore reproductive function in FHA patients. Remarkably, administering kisspeptin to women with FHA can acutely increase LH and FSH levels – in one study, a single kisspeptin injection produced a rapid ten-fold surge in LH in these women (Stress, kisspeptin, and functional hypothalamic amenorrhea) (Functional Hypothalamic Amenorrhea - Mayo Clinic Proceedings). This response was greater than that seen in healthy women, suggesting that the dormant GnRH system in FHA is capable of reactivation when jump-started by kisspeptin. Continuous infusion of kisspeptin has also been shown to temporarily restore LH pulsatility in women with amenorrhea (Increasing LH Pulsatility in Women With Hypothalamic ...). These findings highlight a potential therapeutic role for kisspeptin in conditions of hypothalamic amenorrhea or other states of low GnRH output. By bypassing upstream inhibitions (like stress or energy deficit signals) and directly stimulating GnRH release, kisspeptin could help resume normal menstrual function in affected women.

• Polycystic Ovary Syndrome (PCOS) and Metabolic Disorders: PCOS is characterized by ovulatory dysfunction and often elevated LH levels and androgens. Some studies have found altered kisspeptin signaling in PCOS, and there is interest in how kisspeptin interacts with the abnormal hormonal milieu of PCOS. Conversely, in metabolic disorders (obesity, diabetes) associated with male hypogonadism or female subfertility, kisspeptin may be a key link. It has been proposed that kisspeptin neurons sense metabolic cues (like leptin, insulin) and thus couple energy status to fertility ( Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction - PMC ). In states of energy excess (obesity) or deficit (undernutrition), kisspeptin levels and receptor sensitivity may change, leading to reproductive hormonal imbalances. For instance, obesity in men can suppress kisspeptin and contribute to lower testosterone (a form of functional hypogonadism). While no kisspeptin-based therapy is yet established for PCOS or obesity-related infertility, these remain areas of active research. Modulating the kisspeptin pathway (either enhancing it in conditions of deficiency or tempering it in conditions of excess) could become a future strategy to treat reproductive dysfunctions tied to metabolism ( Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction - PMC ) ( Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction - PMC ).

• Sexual Dysfunction (HSDD – Hypoactive Sexual Desire Disorder): An exciting new frontier is the use of kisspeptin to treat low sexual desire. Aside from its hormonal effects, kisspeptin also influences brain regions involved in sexual behavior and emotion (Kisspeptin and neurokinin B: roles in reproductive health - PubMed). Recent clinical trials have tested intravenous kisspeptin infusions in women and men suffering from HSDD, a condition of chronically low sexual desire. The results have been promising: kisspeptin improved sexual brain processing and desire in both men and women with HSDD (Kisspeptin hormone injection could treat low sex drive in women and men | Imperial News | Imperial College London) (Kisspeptin hormone injection could treat low sex drive in women and men | Imperial News | Imperial College London). In these placebo-controlled studies (published in 2023), kisspeptin administration was associated with increased activity in brain pathways related to attraction and arousal, increased penile tumescence in men, and enhanced sexual excitement in women, without significant side effects (Kisspeptin may enhance sexual arousal for men with hypoactive ...) (Kisspeptin hormone injection could treat low sex drive in women and men | Imperial News | Imperial College London). Importantly, these pro-sexual effects occurred even without large changes in testosterone or other hormones, suggesting kisspeptin may act on the limbic system directly to modulate sexual desire (Kisspeptin hormone injection could treat low sex drive in women and men | Imperial News | Imperial College London). This positions kisspeptin as a potential first-in-class pharmacological treatment for HSDD in both sexes. While more research is needed, these findings lay the groundwork for kisspeptin-based therapies for psychosexual disorders, addressing a significant unmet need in sexual medicine.

In summary, the “benefits” of kisspeptin in reproductive health are twofold: physiologically, it is indispensable for normal hormonal regulation and fertility; and therapeutically, harnessing kisspeptin offers novel ways to manage reproductive and hormonal disorders. From enabling puberty and ovulation to potentially treating infertility and sexual dysfunction, kisspeptin’s impact is broad and profound. Ongoing clinical trials are further exploring its uses – for example, as a diagnostic test for delayed puberty, as a treatment for infertility due to hypothalamic amenorrhea, and even intranasal kisspeptin administration for convenience (Intranasal kisspeptin administration rapidly stimulates gonadotropin ...). Its co-regulators (like neurokinin B) have already yielded new drugs (e.g. NKB antagonists for menopausal hot flashes (Kisspeptin and neurokinin B: roles in reproductive health - PubMed)), hinting that kisspeptin-based drugs may not be far behind.

Conclusion

Kisspeptin has emerged as a master regulator of the reproductive endocrine axis. It connects various physiological signals – hormonal, metabolic, and neural – to the control of GnRH and thus governs puberty, menstrual cycles, and fertility in women and men. The HPG axis cannot function properly without kisspeptin’s input, which is why it is often dubbed the “on-switch” for reproduction. Our growing understanding of kisspeptin’s mechanisms has translated into exciting clinical research, positioning kisspeptin and its analogs as potential therapies for a range of conditions from infertility to low libido. While no kisspeptin-derived treatments are standard of care yet (aside from research settings), the coming years are likely to see these discoveries move from “bench to bedside.” The unique ability of kisspeptin to safely modulate the reproductive hormones – as evidenced by trials improving IVF safety and treating sexual disorders – underscores its therapeutic promise. In conclusion, kisspeptin is not only fundamental for normal reproductive health and hormonal regulation, but it is also a beacon of hope for innovative treatments in reproductive medicine ( Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction - PMC ) (Kisspeptin and neurokinin B: roles in reproductive health - PubMed).

Sources:

1. Koysombat K, et al. (2025). Physiol Rev 105(2):707-764 – Roles of kisspeptin in puberty, menstrual cycle, and therapeutic applications (Kisspeptin and neurokinin B: roles in reproductive health - PubMed) (Kisspeptin and neurokinin B: roles in reproductive health - PubMed).

2. Indrawati D, et al. (2020). Reprod Med Int 6(2): – Differences of HPG axis in Male vs Female (kisspeptin neuron distribution and surge) (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female) (Different of Hypothalamic-Pituitary-Gonadal Axis in Male and Female).

3. Chan Y-M, et al. (2014). J Clin Endocrinol Metab 99(12):E2762-71 – Kisspeptin as a stimulus test in GnRH-deficient patients (Exogenous kisspeptin administration as a probe of GnRH neuronal function in patients with idiopathic hypogonadotropic hypogonadism - PubMed) (Exogenous kisspeptin administration as a probe of GnRH neuronal function in patients with idiopathic hypogonadotropic hypogonadism - PubMed).

4. Abbara A, et al. (2015). J Clin Endocrinol Metab 100(10):3322-31 – Kisspeptin-54 triggers oocyte maturation in IVF patients at risk of OHSS (Kisspeptin and neurokinin B: roles in reproductive health - PubMed) (Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome (OHSS) During In Vitro Fertilization (IVF) Therapy - PubMed).

5. Comninos AN, et al. (2023). JAMA Network Open 6(2):e2252749 – Kisspeptin therapy in men and women with hypoactive sexual desire disorder (Kisspeptin hormone injection could treat low sex drive in women and men | Imperial News | Imperial College London) (Kisspeptin hormone injection could treat low sex drive in women and men | Imperial News | Imperial College London).

6. Ferro VA, et al. (2024). J Diabetes 16(4):e13541 – Kisspeptin linking metabolism and reproduction (therapeutic targets in obesity/amenorrhea) ( Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction - PMC ) ( Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction - PMC ).